Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 9/20 | 0.40 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.40 |
| ▸ | SCN10A | Q9Y5Y9 | 3/20 | 0.40 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.38 |
| ▸ | MAP4K2 | Q12851 | 1/20 | 0.38 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.37 |
| ▸ | DHODH | Q02127 | 3/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10129599 | 0.89 | TRPV1 (0.40) | TRPV1SCN8ASCN10ARXFP1 | |
| SCHEMBL495861 | 0.86 | TRPV1 (0.43) | TRPV1SCN8ASCN10ATNK2MAP4K2 | |
| SCHEMBL496600 | 0.83 | SCN10A (0.43) | TRPV1SCN8ASCN10AACKR3RXFP1 | |
| SCHEMBL496591 | 0.83 | TRPV1 (0.41) | TRPV1SCN8ASCN10ATNK2MAP4K2 | |
| SCHEMBL496279 | 0.76 | TRPV1 (0.55) | TRPV1 | |
| Hydrochloric Acid SCHEMBL496323 | 0.74 | TRPV1 (0.51) | TRPV1 | |
| Hydrochloric Acid SCHEMBL496044 | 0.73 | TRPV1 (0.50) | TRPV1 | |
| SCHEMBL10129633 | 0.73 | TRPV1 (0.53) | TRPV1FLT3 | |
| SCHEMBL10129648 | 0.73 | TRPV1 (0.53) | TRPV1FLT3 | |
| SCHEMBL496257 | 0.73 | TRPV1 (0.53) | TRPV1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1955697-B1 | 2-AMINOBENZAMIDE DERIVATIVES AS VANILLOID RECEPTOR 1 (VR1) INHIBITORS USEFUL FOR THE TREATMENT OF PAIN OR BLADDER FUNCTION DISORDER | ASTELLAS PHARMA INC (JP) | 2012-05-02 | — | — | EP | disclosed |
| US-8106190-B2 | 2-aminobenzamide derivatives | ASTELLAS PHARMA INC. (JP) | 2012-01-31 | — | — | US | disclosed |
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1955697-A1 | 2-AMINOBENZAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2008-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233900-A1 | 2-AMINOBENZAMIDE DERIVATIVE | TRPV1, TRPV2, TRPV5 | TRPV1 1/4885SCN8A 418/4885SCN10A 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.